Nektar Therapeutics (NASDAQ:NKTR) has been under a strong bear grip, hence the stock is down -7.07% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.3% in the past 1 week. The stock has risen by 3.61% in the past week indicating that the buyers are active at lower levels, but the stock is down -5.57% in the past 4 weeks.
The company shares have rallied 26.23% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $17.55 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $14.94 and the 200 Day Moving Average price is recorded at $14.06.
The stock has recorded a 20-day Moving Average of 1.3% and the 50-Day Moving Average is 1.51%.
Nektar Therapeutics (NASDAQ:NKTR): stock turned positive on Friday. Though the stock opened at $14.37, the bulls momentum made the stock top out at $14.94 level for the day. The stock recorded a low of $14.335 and closed the trading day at $14.92, in the green by 4.34%. The total traded volume for the day was 833,434. The stock had closed at $14.3 in the previous days trading.
In an insider trading activity, Chess Robert, director of Nektar Therapeutics, unloaded 5,000 shares at an average price of $14.1 on July 1, 2016. The total amount of the transaction was worth $70,500, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.